Aurobindo Pharma Limited

NSEI:AUROPHARMA Stock Report

Market Cap: ₹855.3b

Aurobindo Pharma Valuation

Is AUROPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AUROPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AUROPHARMA (₹1472.7) is trading below our estimate of fair value (₹1581.74)

Significantly Below Fair Value: AUROPHARMA is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AUROPHARMA?

Other financial metrics that can be useful for relative valuation.

AUROPHARMA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.9x
Enterprise Value/EBITDA13.8x
PEG Ratio1.9x

Price to Earnings Ratio vs Peers

How does AUROPHARMA's PE Ratio compare to its peers?

The above table shows the PE ratio for AUROPHARMA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.1x
500257 Lupin
43.9x19.0%₹992.7b
ALKEM Alkem Laboratories
35.7x11.3%₹733.3b
ZYDUSLIFE Zydus Lifesciences
24.7x3.1%₹1.0t
500124 Dr. Reddy's Laboratories
20.2x-1.9%₹1.1t
AUROPHARMA Aurobindo Pharma
24.3x12.6%₹855.3b

Price-To-Earnings vs Peers: AUROPHARMA is good value based on its Price-To-Earnings Ratio (24.3x) compared to the peer average (31.1x).

Price to Earnings Ratio vs Industry

How does AUROPHARMA's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.5%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.5%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: AUROPHARMA is good value based on its Price-To-Earnings Ratio (24.3x) compared to the Indian Pharmaceuticals industry average (40.4x).

Price to Earnings Ratio vs Fair Ratio

What is AUROPHARMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AUROPHARMA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.3x
Fair PE Ratio42.6x

Price-To-Earnings vs Fair Ratio: AUROPHARMA is good value based on its Price-To-Earnings Ratio (24.3x) compared to the estimated Fair Price-To-Earnings Ratio (42.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AUROPHARMA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,472.70
₹1,591.15
+8.0%
9.9%₹1,930.00₹1,270.00n/a27
Oct ’25₹1,438.30
₹1,558.78
+8.4%
11.4%₹1,930.00₹1,164.00n/a27
Sep ’25₹1,569.40
₹1,550.00
-1.2%
11.7%₹1,930.00₹1,164.00n/a26
Aug ’25₹1,432.85
₹1,342.19
-6.3%
12.1%₹1,640.00₹980.00n/a26
Jul ’25₹1,211.80
₹1,299.77
+7.3%
11.4%₹1,500.00₹980.00n/a26
Jun ’25₹1,185.70
₹1,291.50
+8.9%
11.7%₹1,500.00₹980.00n/a26
May ’25₹1,153.50
₹1,188.88
+3.1%
11.2%₹1,424.00₹940.00n/a25
Apr ’25₹1,113.35
₹1,171.80
+5.2%
10.3%₹1,400.00₹940.00n/a25
Mar ’25₹1,026.40
₹1,161.81
+13.2%
10.0%₹1,375.00₹940.00n/a26
Feb ’25₹1,070.80
₹1,085.32
+1.4%
14.1%₹1,370.00₹710.00n/a25
Jan ’25₹1,080.15
₹999.00
-7.5%
13.7%₹1,200.00₹615.00n/a27
Dec ’24₹1,033.75
₹999.00
-3.4%
13.7%₹1,200.00₹615.00n/a27
Nov ’24₹859.20
₹868.00
+1.0%
15.5%₹1,055.00₹516.00n/a27
Oct ’24₹914.35
₹854.67
-6.5%
14.6%₹1,055.00₹600.00₹1,438.3027
Sep ’24₹825.55
₹854.67
+3.5%
14.6%₹1,055.00₹600.00₹1,569.4027
Aug ’24₹818.50
₹675.71
-17.4%
8.1%₹809.00₹554.00₹1,432.8528
Jul ’24₹727.35
₹666.44
-8.4%
8.2%₹809.00₹554.00₹1,211.8027
Jun ’24₹658.70
₹653.11
-0.8%
10.0%₹809.00₹506.00₹1,185.7027
May ’24₹617.00
₹586.11
-5.0%
10.9%₹710.00₹450.00₹1,153.5027
Apr ’24₹518.10
₹567.96
+9.6%
12.4%₹710.00₹430.00₹1,113.3527
Mar ’24₹463.65
₹571.15
+23.2%
12.5%₹710.00₹430.00₹1,026.4027
Feb ’24₹412.70
₹574.35
+39.2%
13.1%₹710.00₹430.00₹1,070.8026
Jan ’24₹438.30
₹587.73
+34.1%
12.0%₹710.00₹430.00₹1,080.1526
Dec ’23₹468.90
₹613.56
+30.8%
19.8%₹1,100.00₹430.00₹1,033.7527
Nov ’23₹549.75
₹685.14
+24.6%
15.8%₹1,100.00₹475.00₹859.2029
Oct ’23₹510.60
₹678.77
+32.9%
11.5%₹835.00₹475.00₹914.3530

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y